

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



中生北控生物科技股份有限公司
BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION*
(a joint stock limited company incorporated in the People's Republic of China with limited liability)
(Stock Code: 8247)

QUARTERLY UPDATE ON SUSPENSION OF TRADING

This announcement is made by Biosino Bio-Technology and Science Incorporation* (the “**Company**”) pursuant to Rules 17.10 and 17.26A of the Rules (the “**GEM Listing Rules**”) Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements (the “**Announcements**”) of the Company dated 31 March 2020, 13 May 2020, 17 June 2020 respectively in relation to, among other things, delay in publication of its annual results and annual report for the year ended 31 December 2019, delay in publication of its quarterly results and quarterly report for the three months ended 31 March 2020, the suspension of trading in the H shares of the Company on the Stock Exchange and resumption guidance given by the Stock Exchange. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcements.

The Board wishes to update the shareholders and potential investors of the Company of the latest development on the Group's business operations and the progress of actions taken to comply with the Resumption Guidance.

UPDATE ON THE BUSINESS OPERATIONS OF THE GROUP

The Group is principally engaged in the manufacture, sale and distribution of in-vitro diagnostic reagent products.

The Company was recently listed as one of hundreds of epidemic prevention companies to receive key financial support to be given by the Beijing Government as part of its measures to prevent COVID-19. However, even though the Company has been operating during the COVID-19 pandemic, the number of patients being treated and the testing service business at the hospitals on mainland China decreased substantially during the period, which significantly affected the Company's diagnostic business. Accordingly, the Group's day-to-day operations and financial position were impacted by the COVID-19 pandemic.

As at the date of this announcement, the Group is carrying on its normal day-to-day operations. The Group will continue to review its existing businesses from time to time and strive to improve the business operations and financial position of the Group. It has been the business strategy of the Group to proactively seek for potential business and investment opportunities with the aim of broadening its source of income and maximising return to the shareholders.

RESUMPTION PROGRESS

Resumption plan

To resume trading in its shares, the Company submitted the resumption plan to the Stock Exchange on 30 June 2020. However, the Company has not entered into any agreements regarding the resumption plan. The Company will make further announcement regarding a feasible timetable for its fulfilment of the Resumption Conditions as soon as they are available.

DELAY IN PUBLICATION OF ANNUAL RESULTS, FIRST QUARTERLY RESULTS AND DESPATCH OF ANNUAL REPORT AND FIRST QUARTERLY REPORT

As the publication of the 2019 Annual Results is still pending, the Company is unable to make the 2020 First Quarterly Results to its shareholders within the prescribed time in accordance with the GEM Listing Rules.

CONTINUED SUSPENSION OF TRADING IN H SHARES

Trading in the H shares of the Company has been suspended since 9:00 a.m. on 1 April 2020 and will continue to be suspended until further notice. The Company will keep the public informed of the latest developments by making further announcement(s) as and when appropriate.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares or other securities of the Company.

For and on behalf of the Board
Biosino Bio-Technology and Science Incorporation*
Wu Lebin
Chairman, Executive Director and President

Beijing, the PRC, 30 June 2020

As at the date of this announcement, the Board comprises:

Chairman and executive Director

Mr. Wu Lebin (吳樂斌先生)

Vice chairman and non-executive Director

Dr. Sun Zhe (孫哲博士)

Vice chairman and executive Director

Mr. Chen Jintian (陳錦添先生)

Executive Directors

Dr. Xu Cunmao (許存茂博士) and Mr. Chen Jianhua (陳建華先生)

Non-executive Director

Ms. Cheng Yali (程亞利女士)

Independent non-executive Directors

Dr. Zheng Yongtang (鄭永唐博士), Mr. Ren Fujin (任孚今先生) and Ms. Li Li (李瀅女士)

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, (1) the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and (2) there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the GEM website with the domain name of www.hkgem.com on the “Latest Company Announcements” page for at least 7 days from the date of its posting and on the website of the Company at www.zhongsheng.com.cn.

* For identification purposes only